AGIO Latest Press Releases

-- November 5, 2026 --

Agios Reports Third Quarter 2026 Financial Results and Provides Business Update Globe Newswire 6:30 AM

-- November 4, 2026 --

Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026 Globe Newswire 9:01 AM

-- October 30, 2026 --

Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA Globe Newswire 7:00 AM

-- October 8, 2026 --

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET Globe Newswire 7:00 AM

-- August 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO PRNewswire 11:02 PM

-- July 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO PRNewswire 10:00 AM

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 6:30 AM

-- July 28, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO Globe Newswire 5:24 PM

-- July 21, 2026 --

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease Globe Newswire 7:00 AM

-- July 7, 2026 --

U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease Globe Newswire 7:00 AM

-- June 29, 2026 --

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes